Table 2.
CD4+/CD8+ T-Cell Ratios, Percentage Expression of CXCR3 and CCR5 on CD4+ and CD8+ T Cells, and CXCL10, CCL2, and CCL3 Levels in Blood and CSF Samples at cART Initiation in Patients With No ND and Patients With C-IRIS
| Blood |
CSF |
|||||
|---|---|---|---|---|---|---|
| No ND | C-IRIS | P Value | No ND | C-IRIS | P Value | |
| CD4+/CD8+ T-cell ratio | 0.30 (0.11–0.74) | 0.14 (0.02–0.43) | .03 | 0.06 (0.02–0.13) | 0.02 (0.01–0.07) | .046 |
| Proportion of CD4+ T cells, % | ||||||
| CXCR3+CCR5− | 12.6 (4.5–21.6) | 10.8 (2.9–17.3) | NS | 21.4 (10.1–34.9) | 15.9 (8.4–32.6) | NS |
| CXCR3+CCR5+ | 4.4 (1.8–8.9) | 2.7 (0.8–7.9) | NS | 38.7 (20.5–51.8) | 43.0 (30.4–60.8) | NS |
| CXCR3−CCR5+ | 12.3 (3.8–31.0) | 14.5 (3.1–34.0) | NS | 11.5 (4.7–17.2) | 16.5 (3.6–26.0) | NS |
| Proportion of CD8+ T cells, % | ||||||
| CXCR3+CCR5− | 9.9 (6.2–16.3) | 11.4 (5.9–17.1) | NS | 4.4 (2.1–7.9) | 4.2 (1.9–8.3) | NS |
| CXCR3+CCR5+ | 21.4 (13.8–30.0) | 12.6 (10.4–25.8) | .03 | 74.0 (60.0–83.9) | 77.4 (71.3–86.0) | NS |
| CXCR3−CCR5+ | 26.3 (18.4–36.5) | 27.2 (16.5–41.2) | NS | 15.0 (6.3–27.2) | 11.0 (8.2–23.0) | NS |
| CXCL10, pg/mL | 3.0 (1.8–5.0) ×103 | 2.5 (1.8–4.8) × 103 | NS | 5.5 (2.4–9.4) × 104 | 2.6 (1.7–7.0) × 104 | NS |
| CCL2, pg/mL | 4.9 (2.8–9.8) ×101 | 6.2 (2.8–11.7) ×101 | NS | 2.5 (1.6–5.1) × 102 | 4.4 (2.0–11.7) × 102 | NS |
| CCL3, pg/mL | 1.8 (0.1–19.1) | 1.7 (1.0–7.8) | NS | 7.1 (4.2–15.7) | 12.7 (6.6–242.8) | NS |
Abbreviation: cART, combination antiretroviral therapy; C-IRIS, cryptococcosis-associated immune reconstitution inflammatory syndrome; CSF, cerebrospinal fluid; ND, neurological deterioration; NS, not significant.
a Values represent medians (interquartile ranges).